Proteostasis signs on Biogen Idec to help with Usp14 inhibitor program
Proteostasis Therapeutics Inc. (developing therapies for orphan and regenerative diseases and cystic fibrosis) and Biogen Idec Inc. have signed a worldwide R&D deal involving therapeutics that inhibit the ubiquitin specific peptidase 14 (Usp14) enzyme, offering a disease-modifying approach to conditions involving toxic protein aggregation.
- Large Molecule
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com